TB Alliance

GHIT leverages Japanese innovation in fight against TB

The Global Health Innovative Technology Fund (GHIT Fund), a new public-private partnership that’s bringing Japanese research and development (R&D) to the global fight against infectious disease, will announce at the 5th Tokyo International Conference on African Development (TICAD V) a series of historic agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis, and other afflictions that prey mainly on the poorest of the poor.

Read More →

TB Alliance licenses late-stage TB program to CSIR-OSDD

TB Alliance, an international non-profit organization which develops better, faster-acting, and affordable TB drugs, has announced that it has granted a license to and is working with the Open Source Drug Discovery (OSDD) programme of Council of Scientific and Industrial Research (CSIR) to develop and commercialize a promising new tuberculosis (TB) regimen for use within India. CSIR is an Indian governmental institution, which provides scientific and industrial R&D that maximizes the economic, environmental, and societal benefits for the people of India.

Read More →

UNITAID and TB Alliance call for more action against childhood tuberculosis

In TB fight, children must be a priority – World TB Day March 24

Read More →

Improving the therapeutic potential of pyrazinamide

Pyrazinamide (PZA) is an incredibly important sterilizing agent in the treatment of tuberculosis and is considered responsible for reducing the duration of treatment from the previous 9-12 months, to the current short-course of 6 months produced by the standard regimen (HRZE).Beyond its contribution in the current  first-line regimen, the TB Alliance, through its ongoing novel regimen development program is finding that PZA is critical to any treatment shortening regimen, including those that contain newer agents currently in clinical development.  PZA has the ability to synergize with other drugs and this synergy drives the treatment-shortening potential of experimental regimens, such as PaMZ (PA-824 + moxifloxacin + pyrazinamide) currently under clinical development. However, resistance to PZA is on the rise, creating potential problems for PZA-containing regimens in development. Yet, there may be ways to circumvent this resistance. Investigating whether this is possible is the focus of a 1-year, $250,000 grant from the US NIH ACTG.

Read More →

TB Alliance receives grant from UNITAID to develop pediatric TB drugs

Grant to reshape market forces, catalyze development to improve treatment of childhood TB.

Read More →

TB Alliance and FIND announce collaboration to promote development of TB drugs and diagnostics

NEW YORK, NY/GENEVA, SWITZERLAND A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

Read More →

TB Alliance to present research at ICAAC 2012

The TB Alliance and its partners will be presenting recent advances in TB research and development at the ICAAC 2012 conference. Posters and presentations will detail important findings from the The University of Auckland and TB Alliance’s lead preclinical TB drug candidate, the nitroimidazole, TBA-354.

Read More →

Trial signals major milestone in hunt for new TB drugs

Lancet paper finds novel drug regimen could be more effective than existing treatments; TB Alliance’s trial to test drugs in combination saves years in research time.

Read More →

TB Alliance launches combination drug trial, establishes new pathway to TB and MDR-TB treatment

Goal is to find new treatment that takes months, not years, and cures multiple forms of tuberculosis.

Read More →

TB Alliance launches toolkit to support TB R&D advocacy

The TB Alliance and other organizations spearheading the research and development of new and improved tools to treat, diagnose, and prevent TB need your help to ensure that appropriate levels of political commitment and financial investment are dedicated toward TB R&D.

Read More →

Page 5 of 6 · Total posts: 10

←First 4 5 6 Last→